Studies on lung adenocarcinoma have shown [15, 16] that the EGFR ligand is rapidly released to activate the EGFR and mitogen-activated protein kinase signaling pathways when lung cancer cells are stimulated with estrogen. The gene discussed is EGFR; the disease is lung carcinoma.